1. Non-Hodgkin lymphoma risk in adults living with HIV across five continents The AIDS-defining Cancer Project Working Group of leDEA and COHERE in EuroCoord
- Author
-
Rohner, Eliane Butikofer, Lukas Schmidlin, Kurt Sengayi, Mazvita Maskew, Mhairi Giddy, Janet Moore, Richard D. and Goedert, James J. Gill, M. John Silverberg, Michael J. and Patel, Pragna Castilho, Jessica Hoy, Jennifer Sohn, Annette and Bani-Sadr, Firouze Taylor, Ninon Paparizos, Vassilios Le Moing, Vincent Bonnet, Fabrice Verbon, Annelies Vehreschild, Jorg Janne Post, Frank A. Sabin, Caroline Mocroft, Amanda and Dronda, Fernando Obel, Niels Grabar, Sophie Spagnuolo, Vincenzo Antinori, Andrea Quiros-Rol-dan, Eugenia Mussini, Cristina Miro, Jose M. Meyer, Laurence Hasse, Barbara and Konopnicki, Deborah Roca, Bernardino Boue, Francois Barger, Diana Raben, Dorthe Clifford, Gary M. Franceschi, Silvia and Brockmeyer, Norbert Egger, Matthias Bohlius, Julia and AIDS-Defining Cancer Project Work
- Abstract
Objective: To compare non-I lodgkin lymphoma (NHL) incidence rates in adults who started antiretroviral therapy (ART) across the Asia-Pacific, South Africa, Europe, Latin, and North America. Methods: We included cohort data of adults living with HIV who started ART after 1995 within the framework of the International epidemiology Databases to Evaluate AIDS (leDEA) and (he Collaboration of Observational HIV Epidemiological Research in Europe (COHERE). We used flexible parametric survival models to compare regional NHL rates at 2 years after ART start and to identify risk factors for NHL. Results: We included 210898 adults with 1.1 million person-years (pys) of follow-up and 1552 incident NHL cases (raw overall incidence rate 142/100000 pys). After adjusting for age at ART start, first-line ART regimen, calendar period of ART start, and especially current CD4(+) cell count, NHL rates were similar across regions for most population groups. However, South African women remained at increased risk of developing NHL compared with their European counterparts [adjusted hazard ratio [aHR] 1.79, 95% CI 1.19-2.701. In Europe, Latin, and North America, NHL risk was highest in MSM (aHR 1.30, 95% CI 1.14-1.48), followed by heterosexual men (referent), and women (aHR 0.66, 95% CI 0.57-0.78). Conclusion: The risk of developing NHL is higher in women in South Africa than in Europe and higher in MSM compared with heterosexual men and women. Reasons for these differences remain unclear. Early ART access and regular patient monitoring to avert low CD4(+) cell counts remain key for NHL prevention. copyright (C) 2018 WolLers Kluwer Health, Inc. All rights reserved.
- Published
- 2018